Clinical trials: GENE EXPRESSION
Cancer
The Expression of Antigens in Bone Marrow Samples From Volunteering Donors.
Antigen expression levels in bone marrow from volunteering donors will be analyzed. The results of this analysis will be used to establish a clinical test to identify cancer patients who could qualify to receive an…
- Trial name
- NCT00706199
- Testing
- Bone marrow aspiration
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
glp1 Agonist, Gene Expression
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared…
- Conditions
- glp1 Agonist, Gene Expression, Skin Laxity
- Trial name
- NCT07224880
- Testing
- ellacor
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytrellis Biosystems, Inc.
Metastatic Colorectal Cancer
Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.
The purpose of this study is to evaluate the safety and efficacy of the experimental drug abituzumab (EMD525797) in combination with cetuximab and FOLFIRI in RAS wild-type, left-sided, metastatic colorectal cancer patients with…
- Trial name
- AMELION (NCT03688230)
- Testing
- abituzumab
- Sponsor
- SFJ Pharmaceuticals X, LTD.
Head and Neck Squamous Cell Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies.
- Trial name
- VELOCITY-HNSCC (NCT06727565)
- Testing
- Domvanalimab, Zimberelimab, Paclitaxel
- Where
- 23 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumor
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression.
- Trial name
- NCT05163041
- Testing
- BT7480, Nivolumab
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- BicycleTx Limited
Usage of Prescription Opioids
Determining Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction
This is a clinical study on patients who have been prescribed opioids (narcotic pain relievers) for the treatment of pain, to determine what genetic factors influence outcome of treatment.
- Trial name
- NCT01562353
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Analgesic Solutions
Gastric Cancer, Pancreatic Cancer
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
This is an open label, multi-center, Phase 1 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in advanced solid tumors with positive CLDN18.2 expression
- Conditions
- Gastric Cancer, Pancreatic Cancer, Advanced Ovarian Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05472857
- Testing
- Claudin 18.2 CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Lung Cancer, NSCLC
Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is…
- Conditions
- Lung Cancer, NSCLC, Lung Adenocarcinoma
- Trial name
- ONC003 (NCT02121925)
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Neoplasms, Solid Tumors
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available…
- Conditions
- Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
- Trial name
- NCT02091141
- Testing
- Trastuzumab, Pertuzumab, Erlotinib
- Where
- 60 sites in United States
- Volunteers
- 673 people
- Sponsor
- Genentech, Inc.
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
- Trial name
- KYLIN-1 (NCT06343064)
- Testing
- Vebreltinib, PLB1004
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Ischemic Stroke, Ischemia
Biomarkers of Acute Stroke in Clinic
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic…
- Conditions
- Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack
- Trial name
- BASIC (NCT03897478)
- Testing
- ISCDX blood test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ischemia Care LLC
Ovarian Cancer
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer.
- Trial name
- NCT01684878
- Testing
- Gemcitabine (Chemotherapy), Paclitaxel (Chemotherapy), Pertuzumab
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Stage IV Renal Cell Cancer
A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)
This is a Phase 1/2, proof-of-principle clinical study to assess safety and efficacy of a intradermally administered tumor vaccine (MGN1601). The study will be conducted in patients with advanced renal cell carcinoma.
- Trial name
- ASET (NCT01265368)
- Testing
- MGN1601
- Where
- 3 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Mologen AG
Non - Small Cell Lung Cancer NSCLC
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of…
- Trial name
- ARCTIC (NCT02352948)
- Testing
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine
- Where
- 201 sites in United States, Australia and 24 more
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
Gene Expression
Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
- Trial name
- Sculptra (NCT05620043)
- Testing
- Sculptra, Radiesse Plus
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Dry Eye Syndrome
SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers
The purpose of this study is to evaluate the ability of SYSTANE® BALANCE and SYSTANE® Gel to improve comfort in subjects with dry eyes.
- Trial name
- NCT01733732
- Testing
- SYSTANE® BALANCE Lubricant Eye Drops, SYSTANE® Gel
- Volunteers
- 54 people
- Sponsor
- Alcon Research
Non-Small Cell Lung Cancer
PD-L1 Expression in Lung Cancer
This study will measure PD-L1 expression in metastatic NSCLC (primary tumour and metastatic lesions) using [99mTc]-NM-01 SPECT/CT and compare to PD-L1 percentage expression determined by immunohistochemistry (IHC).
- Trial name
- PELICAN (NCT04992715)
- Testing
- [99mTc]-NM01 SPECT/CT
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- NanoMab Technology (UK) Limited
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with…
- Trial name
- BE UNIQUE (NCT06506916)
- Testing
- bimekizumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Breast Cancer
Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients
Primary objective: Determine the impact of the Oncotype DX Recurrence Score (RS) on the treatment recommendation made (administration of chemotherapy or not, in addition to hormonotherapy) in a HR+, N- or pN1(mi), Her2- breast…
- Trial name
- SWITCH (NCT01446185)
- Testing
- Oncotype DX breast cancer test
- Where
- 6 sites in France
- Volunteers
- 100 people
- Sponsor
- Genomic Health®, Inc.
Cardiac Transplant Failure, Cardiac Transplant Rejection
Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Trial name
- D-OAR (NCT02178943)
- Where
- 28 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CareDx